Elucidating Mechanism of Immune Evasion in Head and Neck Cancers
Elucidating Mechanism of Immune Evasion in Head and Neck Cancers
批准号:
10392687
负责人:
Jing Hong Wang
金额:
$56.19万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-08-01 至 2023-07-31
关键词:
AddressAntigensAntitumor ResponseCD8B1 geneCharacteristicsClinicCytometryDataDevelopmentExhibitsFailureFoundationsGene ActivationGoalsGrowthHead and Neck CancerHead and Neck Squamous Cell CarcinomaHumanImmuneImmune EvasionImmune checkpoint inhibitorImmune responseImmunologic MarkersImmunotherapyImpairmentKRASG12DKnowledgeLeadLymphocyte ActivationMediatingMethodologyModelingMolecularMusMutationOncogenicPIK3CA genePatientsPatternPhenotypePredispositionPublic HealthRecurrenceRoleSamplingSquamous cell carcinomaT cell responseT-Cell ReceptorT-LymphocyteTherapeuticTimeTransplantationTreatment FailureTumor-Infiltrating Lymphocytesdesignexhaustgain of function mutationimmune checkpoint blockadeimprovedinsightloss of function mutationmouse modelnano-stringneoplastic cellnew therapeutic targetnovelnovel therapeuticspatient populationpersonalized medicineprogrammed cell death protein 1receptorspectrographsuccesstumortumor immunologytumor progression
中文摘要
项目摘要/摘要
为了更好地了解头颈部癌症的免疫逃逸机制,
增强他们对免疫治疗的敏感性。大约90%的头颈癌是鳞状细胞癌
癌症(HNSCC)。复发或转移性HNSCC正在接受检查点封锁治疗
针对程序性死亡1(PD-1)的免疫治疗,PD-1是T细胞上的共同抑制受体。然而,只有一个
部分HNSCC患者对这种抗PD-1治疗有反应(10%-20%)。因此,迫切需要
阐明单一阻断PD-1治疗无反应的潜在机制。除PD-1外,T
细胞表达其他共抑制受体,这些受体也可以诱导免疫抑制表型,例如
淋巴细胞活化基因-3(Lag-3)。然而,这些受体在免疫中的作用仍不明确。
逃避HNSCC(例如,LAG-3)。我们的初步数据显示,HNSCC患者表现出高度的
肿瘤浸润性淋巴细胞(TIL)的异质性模式;然而,其背后的分子驱动因素
差异免疫表型在很大程度上仍不清楚。我们建议的研究完成后,可能会产生
对决定检查点封锁成败的机制的新见解
免疫疗法。我们期望我们的研究能够勾勒出人类神经干细胞的全面免疫格局。
人类病人。所获得的知识将为改进免疫治疗提供关键步骤
以更合理的设计靶向更多的共抑制受体并克服功能障碍
TIL的进展。
我们的长期目标是阐明免疫逃逸机制并改进治疗策略。
HNSCC。HNSCC的发生通常与癌基因突变有关,例如
Smad4、PIK3CA功能增益突变或Notch1功能丧失突变。它在很大程度上仍然
未知HNSCCs是如何逃避免疫识别的。为了解决这个问题,我们用一种
KrasG12D突变和Smad4缺失联合造成的移植性鳞癌模型(KRS-SCC)。我们
发现KRS-SCC肿瘤完全逃脱T细胞介导的抗肿瘤反应,表现为
耗竭的CD8和CD4TIL共表达PD-1和LAG-3。一致地,PD-1和LAG-3的双重抑制
抑制KRS-SCCs的生长。我们计划使用我们独特的小鼠模型和人类患者
以进一步阐明HNSCCs的免疫逃避机制。我们提议的研究可能
大大提高了我们对单一PD-1阻断治疗失败的机制的理解。
与公共卫生的相关性。我们预计,我们的研究将在理解
PD-1阻断治疗HNSCCs失败的机制。我们期待着我们的提议
研究将揭示肿瘤细胞的内在特性与TIL免疫信号之间的联系。
这些研究不仅解决了癌症免疫学中的基本问题,而且还为
在目标人群中开发HNSCCs新疗法的基础
设计合理化。
英文摘要
Project Summary/Abstract
It is crucial to better understand immune evasion mechanisms in head and neck cancers in order to
enhance their susceptibility to immunotherapy. About 90% of head and neck cancers are squamous cell
carcinomas (HNSCC). Recurrent or metastatic HNSCCs are being treated with checkpoint blockade
immunotherapy targeting programmed death 1 (PD-1), a co-inhibitory receptor on T cells. However, only a
subset of HNSCC patients responded to such anti-PD-1 therapy (10-20%). Thus, there is an urgent need to
elucidate mechanisms underlying therapy unresponsiveness to single blockade of PD-1. Apart from PD-1, T
cells express other co-inhibitory receptors that can also induce immunosuppressive phenotypes, such as
lymphocyte activation gene-3 (LAG-3). However, the role of such receptors remains poorly defined in immune
evasion of HNSCCs (e.g., LAG-3). Our preliminary data show that HNSCC patients exhibit a highly
heterogeneous pattern of tumor infiltrating lymphocytes (TILs); however, the molecular drivers underlying such
differential immune phenotypes remain largely unknown. Completion of our proposed studies may generate
novel insight into the mechanisms that determine the success or failure of checkpoint blockade
immunotherapy. We expect our studies to delineate the comprehensive immune landscape of HNSCCs in
human patients. The knowledge gained would provide critical steps toward improving immunotherapy by
targeting additional co-inhibitory receptors with a more rational design and overcoming the dysfunctional
progression of TILs.
Our long-term goal is to elucidate immune evasion mechanism and improve therapeutic strategies of
HNSCCs. HNSCC development often associates with oncogenic mutations, such as heterozygous loss of
Smad4, gain-of-function mutations of PIK3CA or loss-of-function mutations of Notch1. It remains largely
unknown how HNSCCs evade immune recognition. To address this question, we performed studies with a
transplanted SCC model caused by combining KrasG12D mutation and Smad4 loss (termed KRS-SCC). We
found that KRS-SCC tumors completely escaped T cell-mediated anti-tumor responses, manifested with
exhausted CD8 and CD4 TILs co-expressing PD-1 and LAG-3. Consistently, dual inhibition of PD-1 and LAG-3
suppressed the growth of KRS-SCCs. We propose to employ our unique mouse models and human patient
samples to further elucidate immune evasion mechanisms of HNSCCs. Our proposed studies may
substantially advance our understanding in mechanisms that underlie therapy failure of single PD-1 blockade.
Relevance to public health. We envision that our studies will provide substantial advances in understanding
the mechanisms that underlie therapy failure of PD-1 blockade in HNSCCs. We anticipate that our proposed
studies will reveal the connection between intrinsic characteristics of tumor cells and immune signature of TILs.
These studies not only address fundamental questions in cancer immunology but also lay a scientific
foundation for developing novel therapy of HNSCCs in the targeted patient populations with a more
rationalized design.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms of Dual Inhibition of TGFbeta/PD-L1 in HNSCC
-
批准号:10620449
-
项目类别:
-
资助金额:$45.08万
-
财政年份:2022
-
负责人:Jing Hong Wang
-
依托单位:
Mechanisms of Dual Inhibition of TGFbeta/PD-L1 in HNSCC
-
批准号:10541103
-
项目类别:
-
资助金额:$52.37万
-
财政年份:2022
-
负责人:Jing Hong Wang
-
依托单位:
B cell antigen receptor (BCR)-driven mechanistic connection between B cell lymphomagenesis and autoimmunity
-
批准号:10356472
-
项目类别:
-
资助金额:$35.8万
-
财政年份:2021
-
负责人:Jing Hong Wang
-
依托单位:
B cell antigen receptor (BCR)-driven mechanistic connection between B cell lymphomagenesis and autoimmunity
-
批准号:10646137
-
项目类别:
-
资助金额:$35.64万
-
财政年份:2021
-
负责人:Jing Hong Wang
-
依托单位:
Developing newly combined therapeutic strategies for mature B cell lymphoma
-
批准号:10590693
-
项目类别:
-
资助金额:$45.19万
-
财政年份:2021
-
负责人:Jing Hong Wang
-
依托单位:
Developing newly combined therapeutic strategies for mature B cell lymphoma
-
批准号:10366505
-
项目类别:
-
资助金额:$47.66万
-
财政年份:2021
-
负责人:Jing Hong Wang
-
依托单位:
Developing newly combined therapeutic strategies for mature B cell lymphoma
-
批准号:10412143
-
项目类别:
-
资助金额:$45.41万
-
财政年份:2021
-
负责人:Jing Hong Wang
-
依托单位:
B cell antigen receptor (BCR)-driven mechanistic connection between B cell lymphomagenesis and autoimmunity
-
批准号:9973700
-
项目类别:
-
资助金额:$35.57万
-
财政年份:2020
-
负责人:Jing Hong Wang
-
依托单位:
Mechanisms of dual inhibition of TGFbeta/PD-L1 in HNSCC
-
批准号:10306373
-
项目类别:
-
资助金额:$8.21万
-
财政年份:2019
-
负责人:Jing Hong Wang
-
依托单位:
Developing newly combined therapeutic strategies for mature B cell lymphoma
-
批准号:9902383
-
项目类别:
-
资助金额:$46.36万
-
财政年份:2019
-
负责人:Jing Hong Wang
-
依托单位:
Developing newly combined therapeutic strategies for mature B cell lymphoma
-
批准号:10196434
-
项目类别:
-
资助金额:$15.48万
-
财政年份:2019
-
负责人:Jing Hong Wang
-
依托单位:
Elucidating Mechanism of Immune Evasion in Head and Neck Cancers
-
批准号:9976332
-
项目类别:
-
资助金额:$57.04万
-
财政年份:2018
-
负责人:Jing Hong Wang
-
依托单位:
Elucidating Mechanism of Immune Evasion in Head and Neck Cancers
-
批准号:9761536
-
项目类别:
-
资助金额:$57.79万
-
财政年份:2018
-
负责人:Jing Hong Wang
-
依托单位:
A Novel Approach to Evaluate Genetic Variants in Primary Antibody Deficiency
-
批准号:9527609
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2018
-
负责人:Jing Hong Wang
-
依托单位:
Genomic instability mediated via differential DNA repair mechanisms in B cells
-
批准号:8812432
-
项目类别:
-
资助金额:$16.88万
-
财政年份:2014
-
负责人:Jing Hong Wang
-
依托单位:
Role of Target DNA sequences in mutation and DNA Break Generation
-
批准号:8819992
-
项目类别:
-
资助金额:$19.4万
-
财政年份:2014
-
负责人:Jing Hong Wang
-
依托单位:
Mechanisms promoting translocations and mature B cell lymphomas
-
批准号:8820472
-
项目类别:
-
资助金额:$5.41万
-
财政年份:2012
-
负责人:Jing Hong Wang
-
依托单位:
Mechanisms promoting translocations and mature B cell lymphomas
-
批准号:8394820
-
项目类别:
-
资助金额:$32.88万
-
财政年份:2012
-
负责人:Jing Hong Wang
-
依托单位:
Mechanisms promoting translocations and mature B cell lymphomas
-
批准号:8831614
-
项目类别:
-
资助金额:$32.28万
-
财政年份:2012
-
负责人:Jing Hong Wang
-
依托单位:
Mechanisms promoting translocations and mature B cell lymphomas
-
批准号:8717757
-
项目类别:
-
资助金额:$4.51万
-
财政年份:2012
-
负责人:Jing Hong Wang
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: